share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Tatsis Ourania

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Tatsis Ourania

福泰製藥 | 4：持股變動聲明-高管 Tatsis Ourania
美股sec公告 ·  06/06 04:13
牛牛AI助理已提取核心訊息
On June 3, 2024, Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 2,175 shares of common stock at a price of $460 per share. The transaction, conducted on the open market, resulted in a total value of $1,000,500. Following the sale, Tatsis holds a total of 49,098 shares in the company. The sale reflects a direct ownership transaction and is part of the normal course of investment adjustments.
On June 3, 2024, Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 2,175 shares of common stock at a price of $460 per share. The transaction, conducted on the open market, resulted in a total value of $1,000,500. Following the sale, Tatsis holds a total of 49,098 shares in the company. The sale reflects a direct ownership transaction and is part of the normal course of investment adjustments.
2024年6月3日，Vertex Pharmaceuticals Inc.（vertex pharmaceuticals inc）的執行副總裁、首席監管和質量官Ourania Tatsis以每股460美元的價格完成了2175股普通股的出售。此次在公開市場進行的交易總價值為1,000,500美元。在此次交易後，Tatsis持有公司的49,098股股份。本次出售反映了直接持有的交易，是投資調整的正常程序之一。
2024年6月3日，Vertex Pharmaceuticals Inc.（vertex pharmaceuticals inc）的執行副總裁、首席監管和質量官Ourania Tatsis以每股460美元的價格完成了2175股普通股的出售。此次在公開市場進行的交易總價值為1,000,500美元。在此次交易後，Tatsis持有公司的49,098股股份。本次出售反映了直接持有的交易，是投資調整的正常程序之一。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。